Aggiornamento del Report tecnico-scientifico AIFA su KYMRIAH
AIFA has released the update of the technical-scientific report regarding KIMRIAH® (tisagenlecleucel) by Novartis. KIMRIAH® is indicated for the treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse and adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.